Zobrazeno 1 - 10
of 68
pro vyhledávání: '"J W, ATHENS"'
Autor:
J. W. Athens, Homer R. Warner
Publikováno v:
Annals of the New York Academy of Sciences. 113:523-536
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa27d815e3b10e31fe804649f9a978e0
https://doi.org/10.1111/j.1749-6632.1964.tb40689.x
https://doi.org/10.1111/j.1749-6632.1964.tb40689.x
Publikováno v:
Annals of the New York Academy of Sciences. 113:963-967
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b767d193d63d05ba835d3df8037b941
https://doi.org/10.1111/j.1749-6632.1964.tb40716.x
https://doi.org/10.1111/j.1749-6632.1964.tb40716.x
Autor:
Saul E. Rivkin, C. Kent Osborne, John J. Costanzi, J. W. Athens, Danika Lew, Clarence B. Vaughn, Stephanie J. Green, Silvana Martino
Publikováno v:
Cancer. 97(1)
BACKGROUND Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil plus vincristine and prednisone (CMFVP) was compared with single-agent L-phenylalanine mustard (L-PAM) for the treatment of patients with axillary ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d5bd7b848adefd39aff8c9777195e87
https://pubmed.ncbi.nlm.nih.gov/12491501
https://pubmed.ncbi.nlm.nih.gov/12491501
Publikováno v:
Investigational new drugs. 11(2-3)
Fifty-eight evaluable patients with acute leukemia were treated with Mitoxantrone (DHAD) according to two schedules: 14 mg/M2 as a single I.V. pulse dose administered three-week intervals, and 4 mg/M2/day for five days every three weeks. Six of 58 pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4488048679aed4b8cdd49672274997a0
https://pubmed.ncbi.nlm.nih.gov/8262731
https://pubmed.ncbi.nlm.nih.gov/8262731
Autor:
F S, Morrison, K J, Kopecky, D R, Head, J W, Athens, S P, Balcerzak, C, Gumbart, L, Dabich, J J, Costanzi, C A, Coltman, J H, Saiki
Publikováno v:
Leukemia. 6(7)
Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::33648a913488402e7fbea132bf5523f3
https://pubmed.ncbi.nlm.nih.gov/1625490
https://pubmed.ncbi.nlm.nih.gov/1625490
Autor:
Thomas R. Maloney, Mary A. Foulkes, William S. Fletcher, Barth Hoogstraten, J. J. Costanzi, Nazli Gad-el-Mawla, Clarence B. Vaughn, Bill L. Tranum, J. W. Athens
Publikováno v:
Cancer. 54:2248-2256
The Southwest Oncology Group has completed a study of 213 women with the first recurrence of breast cancer. Eligibility included a radical or modified radical mastectomy for cure and recurrence which had received no other form of therapy. Patients we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68eb3932641abd66b821325e9c5e984f
https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co
https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co
Autor:
Glucksberg H, Thomas Maloney, Bill L. Tranum, Joseph D. McCracken, Shelley L. Rasmussen, J. W. Athens, B. Hoogstraten, Nazli Gad-el-Mawla, Saul E. Rivkin, Clarence B. Vaughn, John J. Costanzi
Publikováno v:
Cancer. 50:423-434
The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP to two years of intermittent L-PAM in women with operable breast cancer with histologically positive axillary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::172fad6dc9b76712cf5bc360eb318b00
https://doi.org/10.1002/1097-0142(19820801)50:3<423::aid-cncr2820500307>3.0.co
https://doi.org/10.1002/1097-0142(19820801)50:3<423::aid-cncr2820500307>3.0.co
Autor:
Mary Foulkes, Frank E. Smith, Lawrence H. Baker, Nazil Gad-el-Mawla, Bill L. Tranum, Frank J. Panettiere, J. W. Athens
Publikováno v:
Investigational New Drugs. 1:315-319
The SWOG carried out a Phase II evaluation of rubidazone in patients with advanced breast cancer. Good risk patients were given rubidazone 150 mg/m2 IV every three weeks. Poor risk patients were given a 25% dose reduction at the start of treatment. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a7b26f2a17809b5db4b266194be181
https://doi.org/10.1007/bf00177415
https://doi.org/10.1007/bf00177415
Autor:
J. W. Athens, Mary A. Foulkes, Robert M. O'Bryan, Saul E. Rivkin, J. J. Costanzi, Ronald L. Stephens, Glucksberg H, William A. Knight
Publikováno v:
Breast Cancer Research and Treatment. 3:S27-S33
The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) to two years of intermittent L-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57c63828da9301ebb02455a5d5fa8f04
https://doi.org/10.1007/bf01855124
https://doi.org/10.1007/bf01855124
Publikováno v:
Blood. 38:302-311
In these studies, the DF32P leukokinetic technique has been modified so that neutrophil kinetics may be studied in the nonsteady state. In order to achieve this modification, an acid citrate solution was used in preparing leukocytes for radioactive a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d7ba7ed3ff0dc9af54acf4bfaf7f993
https://doi.org/10.1182/blood.v38.3.302.302
https://doi.org/10.1182/blood.v38.3.302.302